

# Carlisle

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	6.4	nc	(nc-nc)	Male	7	4.1	169.5	(67.9-349.2)
Female	1	2.1	nc	(nc-nc)	Female	7	2.9	239.9	(96.1-494.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
Female	21	25.2	83.2	(51.5-127.2)	Female	5	3.0	164.7	(53.1-384.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	0	3.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.3	nc	(nc-nc)
Male	4	7.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	3	6.4	nc	(nc-nc)	Female	4	2.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	24	22.6	106.4	(68.1-158.3)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.6	nc	(nc-nc)
Male	1	3.8	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	0	2.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.5	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	4.2	119.8	(38.6-279.5)
Male	5	2.5	198.3	(63.9-462.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.7	nc	(nc-nc)	Female	9	5.6	159.6	(72.8-303.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	2.5	nc	(nc-nc)	Male	67	86.2	77.7	(60.2-98.7)
Female	1	0.7	nc	(nc-nc)	Female	73	81.9	89.2	(69.9-112.1)
<b><u>Lung and Bronchus</u></b>									
Male	6	12.0	49.9	(18.2-108.7)					
Female	3	11.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Carver

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	15	13.6	110.0	(61.5-181.4)	Male	10	8.6	116.3	(55.7-214.0)
Female	8	5.3	151.6	(65.3-298.7)	Female	10	7.1	141.6	(67.8-260.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.5	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	0	2.3	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	3	7.7	nc	(nc-nc)
Female	42	59.8	70.3	(50.7-95.0)	Female	12	7.4	162.4	(83.8-283.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.9	nc	(nc-nc)	Male	6	6.4	94.2	(34.4-205.1)
<b><u>Colon / Rectum</u></b>					Female	2	3.1	nc	(nc-nc)
Male	14	14.5	96.7	(52.8-162.2)	<b><u>Ovary</u></b>				
Female	11	15.2	72.5	(36.1-129.7)	Female	3	5.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	3.5	199.8	(80.1-411.7)	Male	5	4.9	102.0	(32.9-238.0)
Female	0	1.0	nc	(nc-nc)	Female	1	5.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	38	43.1	88.1	(62.3-120.9)
Female	1	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	3.3	nc	(nc-nc)
Male	4	7.5	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
Female	8	4.7	171.5	(73.9-338.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.6	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	10.0	60.1	(22.0-130.9)
Male	3	5.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	4.1	121.1	(39.0-282.6)	Female	14	13.7	102.0	(55.7-171.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	4.7	nc	(nc-nc)	Male	165	175.1	94.2	(80.4-109.8)
Female	3	1.8	nc	(nc-nc)	Female	181	197.1	91.8	(78.9-106.2)
<b><u>Lung and Bronchus</u></b>									
Male	33	24.2	136.4	(93.9-191.6)					
Female	41	27.8	147.7	(105.9-200.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Charlemont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	1.9	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	10	6.6	151.4	(72.5-278.4)	Female	1	0.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.4	nc	(nc-nc)
Male	3	2.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	1.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	5.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	0.5	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.1	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.5	nc	(nc-nc)	Female	4	1.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	23	23.5	97.7	(61.9-146.6)
Female	0	0.2	nc	(nc-nc)	Female	28	22.2	126.2	(83.8-182.4)
<b><u>Lung and Bronchus</u></b>									
Male	3	3.4	nc	(nc-nc)					
Female	2	3.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Charlton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	16	13.0	123.4	(70.5-200.3)	Male	4	8.7	nc	(nc-nc)
Female	7	4.0	174.7	(70.0-359.9)	Female	6	6.6	90.9	(33.2-197.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	2.7	223.7	(81.7-486.8)	Male	2	2.8	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	4	2.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	11	7.8	140.8	(70.2-251.9)
Female	53	54.1	98.0	(73.4-128.2)	Female	6	6.2	97.3	(35.5-211.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.9	nc	(nc-nc)	Male	3	6.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	2.7	nc	(nc-nc)
Male	9	15.0	60.0	(27.4-113.9)	<b><u>Ovary</u></b>				
Female	15	12.7	118.4	(66.2-195.3)	Female	2	4.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	3.5	nc	(nc-nc)	Male	7	4.8	146.5	(58.7-301.9)
Female	0	0.8	nc	(nc-nc)	Female	5	4.2	120.4	(38.8-280.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	23	42.9	53.6	(34.0-80.4)
Female	2	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	3.2	nc	(nc-nc)
Male	10	7.8	127.7	(61.2-235.0)	Female	0	1.7	nc	(nc-nc)
Female	3	4.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.9	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	3	0.6	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	16	10.8	147.6	(84.3-239.8)
Male	4	5.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	3.5	nc	(nc-nc)	Female	11	12.2	90.3	(45.0-161.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	4.8	nc	(nc-nc)	Male	140	175.3	79.9	(67.2-94.2)
Female	0	1.5	nc	(nc-nc)	Female	181	170.8	105.9	(91.1-122.6)
<b><u>Lung and Bronchus</u></b>									
Male	21	22.9	91.6	(56.7-140.1)					
Female	25	21.1	118.5	(76.7-175.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chatham

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	15	14.4	104.5	(58.4-172.3)	Male	21	8.0	261.2	(161.6-399.2)
Female	10	4.7	211.4	(101.2-388.8)	Female	14	5.0	281.6	(153.8-472.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.0	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	4	2.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	8	7.2	111.2	(47.9-219.1)
Female	43	42.4	101.5	(73.5-136.8)	Female	7	6.0	117.6	(47.1-242.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	7	5.4	128.5	(51.5-264.8)
<b><u>Colon / Rectum</u></b>					Female	1	2.4	nc	(nc-nc)
Male	16	13.8	115.6	(66.0-187.8)	<b><u>Ovary</u></b>				
Female	14	12.6	110.9	(60.6-186.0)	Female	3	3.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	3.4	nc	(nc-nc)	Male	7	4.8	145.2	(58.2-299.2)
Female	0	0.9	nc	(nc-nc)	Female	6	4.8	125.0	(45.7-272.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	44	39.3	111.8	(81.3-150.1)
Female	1	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	3.3	nc	(nc-nc)
Male	6	6.6	91.1	(33.3-198.3)	Female	1	1.7	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.6	nc	(nc-nc)
Male	0	2.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	5.4	nc	(nc-nc)
Male	9	5.1	178.0	(81.2-337.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	3.3	nc	(nc-nc)	Female	11	9.9	111.4	(55.5-199.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	4.3	nc	(nc-nc)	Male	183	165.2	110.8	(95.3-128.1)
Female	2	1.4	nc	(nc-nc)	Female	169	151.4	111.6	(95.4-129.8)
<b><u>Lung and Bronchus</u></b>									
Male	22	25.1	87.6	(54.9-132.6)					
Female	24	24.7	97.3	(62.3-144.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chelmsford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	51	39.6	128.7	(95.8-169.2)	Male	20	25.4	78.6	(48.0-121.4)
Female	16	15.3	104.7	(59.8-170.0)	Female	20	20.4	98.2	(59.9-151.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	11	7.6	144.8	(72.2-259.1)	Male	8	8.2	97.8	(42.1-192.7)
Female	8	6.5	123.8	(53.3-244.0)	Female	11	7.0	157.8	(78.6-282.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	27	22.6	119.2	(78.6-173.5)
Female	177	170.6	103.8	(89.0-120.2)	Female	16	21.2	75.5	(43.1-122.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	5.4	110.3	(40.3-240.2)	Male	21	19.0	110.5	(68.4-169.0)
<b><u>Colon / Rectum</u></b>					Female	8	8.9	89.5	(38.5-176.4)
Male	40	43.1	92.7	(66.2-126.3)	<b><u>Ovary</u></b>				
Female	44	43.9	100.2	(72.8-134.6)	Female	22	14.5	151.6	(95.0-229.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	10.2	58.7	(21.4-127.7)	Male	18	14.2	126.8	(75.1-200.4)
Female	4	3.0	nc	(nc-nc)	Female	18	15.5	116.5	(69.0-184.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	2.8	nc	(nc-nc)	Male	126	122.8	102.6	(85.5-122.2)
Female	3	2.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	9.6	nc	(nc-nc)
Male	19	22.2	85.6	(51.5-133.8)	Female	4	5.9	nc	(nc-nc)
Female	12	13.5	88.8	(45.8-155.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	5.1	98.5	(31.8-229.9)
Male	4	6.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	2.0	nc	(nc-nc)	Male	13	10.1	128.9	(68.6-220.4)
<b><u>Leukemia</u></b>					Female	29	29.6	97.8	(65.5-140.5)
Male	17	15.9	106.6	(62.1-170.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	25	11.9	210.0	(135.9-310.1)	Female	50	38.0	131.4	(97.6-173.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	14.0	57.2	(24.6-112.8)	Male	513	512.2	100.2	(91.7-109.2)
Female	2	5.0	nc	(nc-nc)	Female	613	567.8	108.0	(99.6-116.9)
<b><u>Lung and Bronchus</u></b>									
Male	64	71.0	90.1	(69.4-115.0)					
Female	79	82.4	95.9	(75.9-119.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chelsea

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	22.1	63.2	(34.5-106.1)	Male	8	16.4	48.9	(21.1-96.4)
Female	10	8.5	117.0	(56.0-215.2)	Female	10	14.4	69.5	(33.3-127.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	6.2	112.2	(45.0-231.2)	Male	5	4.9	102.4	(33.0-238.9)
Female	6	4.9	122.6	(44.8-266.8)	Female	4	4.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	13	14.9	87.2	(46.4-149.1)
Female	96	104.1	92.2	(74.7-112.6)	Female	16	12.9	124.0	(70.8-201.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	7	4.5	155.5	(62.3-320.4)	Male	7	12.4	56.5	(22.6-116.4)
<b><u>Colon / Rectum</u></b>					Female	8	5.4	147.0	(63.3-289.7)
Male	32	27.1	118.0	(80.7-166.6)	<b><u>Ovary</u></b>				
Female	17	26.5	64.2	(37.4-102.8)	Female	5	9.0	55.6	(17.9-129.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	6.0	83.5	(26.9-195.0)	Male	9	8.3	108.6	(49.6-206.2)
Female	0	1.7	nc	(nc-nc)	Female	15	8.8	169.6	(94.9-279.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	3.2	nc	(nc-nc)	Male	51	72.2	70.6	(52.6-92.8)
Female	1	2.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	12	5.7	209.4	(108.1-365.8)
Male	6	14.8	40.6	(14.8-88.3)	Female	4	3.6	nc	(nc-nc)
Female	11	8.1	135.5	(67.5-242.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	6.9	nc	(nc-nc)
Male	4	3.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	7	8.5	82.4	(33.0-169.7)
<b><u>Leukemia</u></b>					Female	41	25.6	160.3	(115.0-217.4)
Male	12	11.1	108.3	(55.9-189.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	11	8.3	132.5	(66.1-237.1)	Female	15	22.2	67.5	(37.8-111.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	14	8.4	166.1	(90.7-278.7)	Male	299	318.7	93.8	(83.5-105.1)
Female	9	2.9	315.0	(143.7-598.0)	Female	381	351.3	108.5	(97.8-119.9)
<b><u>Lung and Bronchus</u></b>									
Male	53	39.0	135.8	(101.7-177.7)					
Female	64	44.1	145.1	(111.7-185.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Cheshire

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	4.7	127.6	(46.6-277.7)	Male	5	2.8	176.8	(57.0-412.7)
Female	2	1.5	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	14	17.1	81.8	(44.7-137.2)	Female	2	2.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.9	nc	(nc-nc)
Male	8	4.8	165.6	(71.3-326.2)	<b><u>Ovary</u></b>				
Female	2	4.3	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	17	15.5	109.6	(63.8-175.5)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.1	nc	(nc-nc)
Male	3	2.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	2.9	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.2	nc	(nc-nc)	Female	7	4.0	174.8	(70.0-360.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	64	59.5	107.5	(82.8-137.3)
Female	0	0.5	nc	(nc-nc)	Female	42	56.9	73.8	(53.1-99.7)
<b><u>Lung and Bronchus</u></b>									
Male	14	8.4	166.8	(91.1-280.0)					
Female	3	8.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Chester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	4	5.9	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.3	nc	(nc-nc)
Male	5	1.6	317.3	(102.3-740.5)	<b><u>Ovary</u></b>				
Female	1	1.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	6	5.1	118.6	(43.3-258.1)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.3	nc	(nc-nc)
Male	2	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.2	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.4	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	0.6	nc	(nc-nc)	Male	23	19.1	120.5	(76.4-180.8)
Female	0	0.2	nc	(nc-nc)	Female	12	18.5	64.8	(33.4-113.2)
<b><u>Lung and Bronchus</u></b>									
Male	2	2.4	nc	(nc-nc)					
Female	2	2.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chesterfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	5.8	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.3	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	1.3	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	5	5.2	95.7	(30.8-223.3)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	0.3	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.1	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.4	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	17	19.1	89.1	(51.9-142.7)
Female	0	0.2	nc	(nc-nc)	Female	10	18.1	55.3	(26.5-101.8)
<b><u>Lung and Bronchus</u></b>									
Male	3	2.4	nc	(nc-nc)					
Female	1	2.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chicopee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	63	64.5	97.7	(75.1-125.0)	Male	25	40.1	62.3	(40.3-91.9)
Female	16	23.6	67.8	(38.7-110.1)	Female	20	31.2	64.1	(39.1-99.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	11	12.1	90.9	(45.3-162.7)	Male	12	12.9	92.9	(48.0-162.3)
Female	12	9.9	121.3	(62.6-211.9)	Female	8	10.6	75.6	(32.6-149.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	2.2	nc	(nc-nc)	Male	30	35.9	83.6	(56.4-119.3)
Female	253	248.9	101.7	(89.5-115.0)	Female	36	32.4	111.1	(77.8-153.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	11	8.0	137.1	(68.4-245.4)	Male	33	29.1	113.3	(78.0-159.2)
<b><u>Colon / Rectum</u></b>					Female	24	13.4	178.5	(114.4-265.7)
Male	97	67.7	143.3	(116.2-174.8)	<b><u>Ovary</u></b>				
Female	62	67.7	91.6	(70.2-117.4)	Female	30	21.7	138.5	(93.4-197.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	16	16.2	98.6	(56.3-160.1)	Male	21	22.6	92.7	(57.4-141.7)
Female	7	4.6	152.1	(60.9-313.4)	Female	26	23.9	108.8	(71.0-159.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	6	4.7	127.9	(46.7-278.4)	Male	115	194.7	59.1	(48.8-70.9)
Female	1	4.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	9	15.3	58.7	(26.8-111.4)
Male	44	34.4	128.0	(93.0-171.9)	Female	9	9.2	97.9	(44.7-185.8)
Female	27	20.2	133.7	(88.1-194.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	10	8.3	120.0	(57.4-220.7)
Male	12	9.4	127.6	(65.9-222.9)	<b><u>Thyroid</u></b>				
Female	0	2.8	nc	(nc-nc)	Male	11	15.3	71.9	(35.8-128.6)
<b><u>Leukemia</u></b>					Female	32	44.5	71.9	(49.1-101.4)
Male	20	25.8	77.6	(47.4-119.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	12	18.7	64.3	(33.2-112.4)	Female	51	55.6	91.7	(68.3-120.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	10	21.7	46.2	(22.1-84.9)	Male	740	813.5	91.0	(84.5-97.8)
Female	7	7.6	92.5	(37.1-190.6)	Female	846	852.3	99.3	(92.7-106.2)
<b><u>Lung and Bronchus</u></b>									
Male	139	114.1	121.9	(102.4-143.9)					
Female	130	123.9	105.0	(87.7-124.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chilmark

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	2	6.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.3	nc	(nc-nc)
Male	4	1.3	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	1.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.0	nc	(nc-nc)
Male	2	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.4	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	19	16.3	116.7	(70.2-182.2)
Female	0	0.2	nc	(nc-nc)	Female	8	19.3	41.4	(17.8-81.5)
<b><u>Lung and Bronchus</u></b>									
Male	2	2.3	nc	(nc-nc)					
Female	2	2.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Clarksburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.7	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	5	8.2	61.3	(19.7-143.0)	Female	1	1.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	2	2.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	3	2.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	0.7	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	8	7.7	104.0	(44.8-205.0)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.6	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.3	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.6	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	30	32.7	91.8	(61.9-131.0)
Female	0	0.3	nc	(nc-nc)	Female	25	27.5	90.8	(58.8-134.1)
<b><u>Lung and Bronchus</u></b>									
Male	5	4.8	103.4	(33.3-241.3)					
Female	5	4.1	122.1	(39.3-284.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Clinton

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	26	13.4	194.1	(126.7-284.4)	Male	6	8.9	67.7	(24.7-147.5)
Female	5	5.1	97.2	(31.3-226.8)	Female	12	7.4	161.2	(83.2-281.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.8	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	4	2.3	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	6	8.0	75.3	(27.5-163.8)
Female	51	59.0	86.4	(64.4-113.7)	Female	8	7.4	108.5	(46.7-213.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.1	nc	(nc-nc)	Male	5	6.9	73.0	(23.5-170.2)
<b><u>Colon / Rectum</u></b>					Female	1	3.1	nc	(nc-nc)
Male	17	14.9	113.9	(66.3-182.4)	<b><u>Ovary</u></b>				
Female	14	15.5	90.4	(49.4-151.7)	Female	5	5.1	98.0	(31.6-228.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	3.6	138.6	(44.7-323.5)	Male	3	4.9	nc	(nc-nc)
Female	4	1.0	nc	(nc-nc)	Female	3	5.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	56	45.2	123.8	(93.5-160.8)
Female	0	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	3.3	nc	(nc-nc)
Male	7	8.0	87.2	(34.9-179.6)	Female	1	2.1	nc	(nc-nc)
Female	5	4.6	108.6	(35.0-253.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.2	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	11	11.4	96.7	(48.2-173.1)
Male	9	5.6	159.7	(72.9-303.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	4.3	139.8	(51.1-304.4)	Female	13	13.2	98.3	(52.3-168.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	4.9	164.3	(70.7-323.7)	Male	199	181.2	109.8	(95.1-126.2)
Female	1	1.7	nc	(nc-nc)	Female	205	197.2	104.0	(90.2-119.2)
<b><u>Lung and Bronchus</u></b>									
Male	28	24.2	115.9	(77.0-167.5)					
Female	37	26.5	139.9	(98.5-192.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Cohasset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	9.4	85.2	(36.7-167.9)	Male	5	6.1	82.3	(26.5-192.1)
Female	6	3.4	175.8	(64.2-382.6)	Female	15	4.4	339.0	(189.6-559.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	6	5.4	111.6	(40.8-243.0)
Female	41	37.0	110.9	(79.6-150.4)	Female	3	4.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.2	nc	(nc-nc)	Male	5	4.6	108.4	(34.9-253.0)
<b><u>Colon / Rectum</u></b>					Female	2	2.0	nc	(nc-nc)
Male	12	10.0	119.9	(61.9-209.4)	<b><u>Ovary</u></b>				
Female	6	9.7	61.8	(22.6-134.5)	Female	4	3.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.5	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	31	30.0	103.3	(70.2-146.6)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.3	nc	(nc-nc)
Male	5	5.3	94.0	(30.3-219.3)	Female	0	1.3	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.0	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	6.3	110.8	(44.4-228.3)
Male	3	3.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	2.7	185.5	(59.8-432.9)	Female	6	8.2	72.9	(26.6-158.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	3.5	nc	(nc-nc)	Male	110	122.9	89.5	(73.6-107.9)
Female	1	1.1	nc	(nc-nc)	Female	131	124.4	105.3	(88.0-124.9)
<b><u>Lung and Bronchus</u></b>									
Male	10	17.1	58.5	(28.0-107.6)					
Female	13	18.2	71.4	(38.0-122.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Colrain

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.5	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	10	7.8	128.7	(61.6-236.7)	Female	0	0.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	3	2.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	5	7.5	66.5	(21.4-155.2)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	0.6	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.4	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.5	nc	(nc-nc)	Female	5	1.8	276.0	(89.0-644.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	22	31.3	70.3	(44.1-106.5)
Female	0	0.2	nc	(nc-nc)	Female	31	25.6	120.9	(82.1-171.6)
<b><u>Lung and Bronchus</u></b>									
Male	3	4.5	nc	(nc-nc)					
Female	4	3.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Concord

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	30	26.5	113.3	(76.4-161.8)	Male	22	16.3	134.6	(84.3-203.8)
Female	10	9.3	107.4	(51.4-197.5)	Female	25	11.3	220.5	(142.6-325.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	4.7	106.6	(34.4-248.8)	Male	4	5.4	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	Female	4	4.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	13	14.7	88.5	(47.1-151.4)
Female	122	94.1	129.6	(107.7-154.8)	Female	9	12.5	72.1	(32.9-136.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.7	nc	(nc-nc)	Male	10	12.1	82.8	(39.6-152.3)
<b><u>Colon / Rectum</u></b>					Female	7	5.2	134.2	(53.8-276.5)
Male	19	28.3	67.2	(40.5-105.0)	<b><u>Ovary</u></b>				
Female	35	27.1	129.4	(90.1-179.9)	Female	14	8.2	171.1	(93.4-287.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	6.7	nc	(nc-nc)	Male	8	9.3	86.1	(37.1-169.7)
Female	0	1.8	nc	(nc-nc)	Female	7	9.6	73.0	(29.3-150.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	87	80.1	108.6	(87.0-133.9)
Female	1	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	6.3	nc	(nc-nc)
Male	8	14.2	56.2	(24.2-110.8)	Female	0	3.7	nc	(nc-nc)
Female	11	7.6	144.6	(72.1-258.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.7	nc	(nc-nc)
Male	1	3.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	5	6.2	81.2	(26.2-189.4)
<b><u>Leukemia</u></b>					Female	15	14.5	103.6	(58.0-170.9)
Male	7	10.3	67.9	(27.2-139.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	7.1	nc	(nc-nc)	Female	23	21.2	108.6	(68.8-163.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	8.9	89.5	(38.6-176.4)	Male	286	332.5	86.0	(76.3-96.6)
Female	4	3.0	nc	(nc-nc)	Female	357	323.7	110.3	(99.1-122.4)
<b><u>Lung and Bronchus</u></b>									
Male	22	46.3	47.5	(29.8-71.9)					
Female	27	47.0	57.4	(37.8-83.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Conway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	2.2	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	7	9.7	72.4	(29.0-149.2)	Female	0	1.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.5	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	2.1	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	8.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.5	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.2	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.6	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.6	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	28	30.1	93.1	(61.9-134.6)
Female	0	0.3	nc	(nc-nc)	Female	21	30.3	69.3	(42.9-105.9)
<b><u>Lung and Bronchus</u></b>									
Male	3	4.0	nc	(nc-nc)					
Female	1	4.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Cummington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.6	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	9	5.1	177.3	(80.9-336.7)	Female	1	0.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.3	nc	(nc-nc)
Male	3	1.6	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	4	1.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	3.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.4	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	0.8	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.4	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	14	17.7	79.0	(43.1-132.5)
Female	1	0.2	nc	(nc-nc)	Female	21	17.3	121.6	(75.2-185.8)
<b><u>Lung and Bronchus</u></b>									
Male	1	2.6	nc	(nc-nc)					
Female	1	2.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dalton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	9.9	70.9	(28.4-146.0)	Male	10	5.9	169.6	(81.2-311.9)
Female	4	3.6	nc	(nc-nc)	Female	4	4.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.7	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.3	nc	(nc-nc)
Female	26	35.6	73.0	(47.7-107.0)	Female	2	4.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	1	4.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	2.0	nc	(nc-nc)
Male	9	10.2	88.7	(40.5-168.3)	<b><u>Ovary</u></b>				
Female	9	10.1	89.1	(40.6-169.1)	Female	3	3.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.4	nc	(nc-nc)	Male	1	3.4	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	3.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	30	26.8	112.0	(75.5-159.8)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.3	nc	(nc-nc)
Male	2	4.9	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.9	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	5.5	nc	(nc-nc)
Male	2	3.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.7	nc	(nc-nc)	Female	10	8.0	124.9	(59.8-229.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	3.1	nc	(nc-nc)	Male	100	118.1	84.7	(68.9-103.0)
Female	0	1.1	nc	(nc-nc)	Female	97	123.0	78.8	(63.9-96.2)
<b><u>Lung and Bronchus</u></b>									
Male	14	17.3	81.0	(44.2-135.9)					
Female	18	18.4	97.6	(57.8-154.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Danvers

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	36	35.4	101.6	(71.2-140.7)	Male	18	21.7	83.1	(49.2-131.3)
Female	11	12.8	85.7	(42.7-153.4)	Female	12	16.1	74.7	(38.6-130.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	11	6.2	176.3	(87.9-315.5)	Male	3	7.0	nc	(nc-nc)
Female	5	5.1	97.4	(31.4-227.4)	Female	3	5.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	15	19.4	77.4	(43.3-127.7)
Female	138	129.3	106.7	(89.6-126.1)	Female	25	17.3	144.9	(93.7-213.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	4.0	nc	(nc-nc)	Male	16	15.5	103.1	(58.9-167.4)
<b><u>Colon / Rectum</u></b>					Female	8	7.1	112.4	(48.4-221.5)
Male	34	36.9	92.1	(63.8-128.7)	<b><u>Ovary</u></b>				
Female	37	37.2	99.5	(70.1-137.2)	Female	13	11.3	115.5	(61.4-197.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	10	8.7	115.0	(55.0-211.4)	Male	12	12.4	97.1	(50.1-169.7)
Female	3	2.4	nc	(nc-nc)	Female	14	13.2	106.4	(58.1-178.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	2.3	nc	(nc-nc)	Male	104	101.2	102.7	(83.9-124.5)
Female	3	1.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	8.3	59.9	(19.3-139.8)
Male	21	18.3	114.8	(71.0-175.5)	Female	5	5.1	98.0	(31.6-228.7)
Female	12	10.5	114.5	(59.1-200.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	7	3.8	183.7	(73.6-378.6)
Male	4	5.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.4	nc	(nc-nc)	Male	11	7.9	138.4	(69.0-247.7)
<b><u>Leukemia</u></b>					Female	30	21.7	138.0	(93.1-197.0)
Male	12	13.8	86.8	(44.8-151.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	15	10.0	149.6	(83.7-246.8)	Female	42	28.5	147.6	(106.3-199.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	11.5	69.7	(30.0-137.3)	Male	434	434.8	99.8	(90.7-109.7)
Female	3	4.1	nc	(nc-nc)	Female	479	447.9	107.0	(97.6-117.0)
<b><u>Lung and Bronchus</u></b>									
Male	66	61.8	106.8	(82.6-135.9)					
Female	54	64.8	83.4	(62.6-108.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dartmouth

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	57	41.2	138.3	(104.7-179.2)	Male	24	25.1	95.6	(61.2-142.3)
Female	18	15.0	120.0	(71.1-189.7)	Female	14	19.0	73.6	(40.2-123.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	7.4	67.3	(21.7-157.0)	Male	5	8.1	61.9	(19.9-144.4)
Female	6	6.1	98.4	(35.9-214.2)	Female	4	6.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	23	22.7	101.2	(64.1-151.8)
Female	129	151.4	85.2	(71.1-101.2)	Female	15	20.2	74.1	(41.4-122.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	4.7	106.2	(34.2-247.9)	Male	17	18.0	94.4	(55.0-151.2)
<b><u>Colon / Rectum</u></b>					Female	10	8.5	117.9	(56.5-216.9)
Male	39	43.2	90.2	(64.1-123.3)	<b><u>Ovary</u></b>				
Female	50	43.7	114.4	(84.9-150.8)	Female	8	13.3	60.0	(25.8-118.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	11	10.1	109.0	(54.4-195.1)	Male	13	14.2	91.2	(48.5-156.0)
Female	2	2.9	nc	(nc-nc)	Female	8	15.7	51.1	(22.0-100.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	3.2	nc	(nc-nc)	Male	142	118.4	119.9	(101.0-141.3)
Female	2	2.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	15	9.7	155.1	(86.8-255.9)
Male	21	21.2	99.1	(61.3-151.5)	Female	11	6.0	183.9	(91.7-329.0)
Female	18	12.2	147.1	(87.1-232.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	5.5	109.6	(40.0-238.5)
Male	7	5.7	122.0	(48.9-251.3)	<b><u>Thyroid</u></b>				
Female	1	1.8	nc	(nc-nc)	Male	7	9.4	74.2	(29.7-152.9)
<b><u>Leukemia</u></b>					Female	33	26.0	126.9	(87.3-178.2)
Male	14	16.2	86.2	(47.1-144.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	11.7	68.3	(29.4-134.6)	Female	32	33.9	94.3	(64.5-133.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	12	13.3	90.4	(46.7-158.0)	Male	517	507.9	101.8	(93.2-111.0)
Female	1	4.7	nc	(nc-nc)	Female	450	526.7	85.4	(77.7-93.7)
<b><u>Lung and Bronchus</u></b>									
Male	71	71.1	99.9	(78.0-126.0)					
Female	42	75.5	55.6	(40.1-75.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dedham

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	29	30.5	95.0	(63.6-136.4)	Male	24	18.6	128.9	(82.6-191.8)
Female	12	12.7	94.2	(48.6-164.6)	Female	19	15.5	122.4	(73.6-191.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	5.5	145.7	(62.7-287.0)	Male	9	6.0	149.0	(68.0-283.0)
Female	5	4.9	102.4	(33.0-239.1)	Female	2	5.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	23	16.9	136.1	(86.3-204.3)
Female	155	123.4	125.7	(106.6-147.1)	Female	16	16.9	94.9	(54.2-154.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	3.8	nc	(nc-nc)	Male	16	13.1	122.5	(69.9-198.9)
<b><u>Colon / Rectum</u></b>					Female	12	6.9	173.8	(89.7-303.7)
Male	31	32.0	96.8	(65.8-137.4)	<b><u>Ovary</u></b>				
Female	28	36.9	75.9	(50.4-109.6)	Female	9	10.8	83.2	(38.0-158.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	7.4	nc	(nc-nc)	Male	14	10.5	132.7	(72.5-222.7)
Female	3	2.4	nc	(nc-nc)	Female	18	13.0	138.0	(81.7-218.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	2.1	nc	(nc-nc)	Male	89	85.6	104.0	(83.5-128.0)
Female	5	1.7	288.0	(92.8-672.0)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	7.2	83.4	(30.5-181.6)
Male	20	15.8	126.8	(77.4-195.9)	Female	8	5.1	157.9	(68.0-311.1)
Female	11	10.1	108.5	(54.1-194.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	3.8	nc	(nc-nc)
Male	4	4.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.4	nc	(nc-nc)	Male	6	7.1	84.8	(31.0-184.7)
<b><u>Leukemia</u></b>					Female	29	20.6	140.7	(94.2-202.1)
Male	12	12.1	99.4	(51.3-173.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	9.8	91.6	(41.8-174.0)	Female	27	26.8	100.8	(66.4-146.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	11	9.5	115.4	(57.5-206.5)	Male	405	373.1	108.6	(98.2-119.7)
Female	6	3.9	152.5	(55.7-331.9)	Female	486	434.2	111.9	(102.2-122.3)
<b><u>Lung and Bronchus</u></b>									
Male	52	52.4	99.2	(74.1-130.1)					
Female	79	63.8	123.9	(98.1-154.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Deerfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	4.3	nc	(nc-nc)	Male	5	3.2	157.6	(50.8-367.8)
Female	4	2.2	nc	(nc-nc)	Female	6	3.1	195.0	(71.2-424.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	21	25.5	82.2	(50.9-125.7)	Female	2	3.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.3	nc	(nc-nc)
Male	6	5.4	111.7	(40.8-243.1)	<b><u>Ovary</u></b>				
Female	6	6.3	94.6	(34.6-206.0)	Female	1	2.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.3	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	14	16.8	83.6	(45.6-140.2)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.1	nc	(nc-nc)
Male	5	3.0	164.4	(53.0-383.7)	Female	0	0.9	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.7	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	4.6	nc	(nc-nc)
Male	0	1.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.7	nc	(nc-nc)	Female	8	5.7	139.4	(60.0-274.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.9	nc	(nc-nc)	Male	55	64.5	85.3	(64.3-111.1)
Female	0	0.7	nc	(nc-nc)	Female	72	83.6	86.1	(67.4-108.4)
<b><u>Lung and Bronchus</u></b>									
Male	3	8.1	nc	(nc-nc)					
Female	7	11.7	60.0	(24.0-123.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Dennis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	50	29.3	170.6	(126.6-224.9)	Male	36	16.2	222.3	(155.7-307.8)
Female	15	10.9	137.4	(76.8-226.6)	Female	22	11.7	187.4	(117.4-283.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	4.2	nc	(nc-nc)	Male	11	5.4	202.2	(100.8-361.8)
Female	2	3.7	nc	(nc-nc)	Female	1	4.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	14	14.4	97.0	(53.0-162.7)
Female	109	100.6	108.3	(89.0-130.7)	Female	11	13.8	79.5	(39.6-142.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.6	nc	(nc-nc)	Male	16	10.5	151.8	(86.7-246.5)
<b><u>Colon / Rectum</u></b>					Female	4	5.6	nc	(nc-nc)
Male	25	27.4	91.2	(59.0-134.7)	<b><u>Ovary</u></b>				
Female	26	28.6	91.0	(59.4-133.3)	Female	15	8.8	170.6	(95.4-281.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	14	6.8	206.5	(112.8-346.5)	Male	12	9.7	123.9	(64.0-216.5)
Female	4	2.1	nc	(nc-nc)	Female	13	10.8	120.0	(63.8-205.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	100	78.8	126.9	(103.2-154.3)
Female	2	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	6.6	nc	(nc-nc)
Male	8	13.1	61.3	(26.4-120.8)	Female	2	3.9	nc	(nc-nc)
Female	5	8.6	58.1	(18.7-135.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.6	nc	(nc-nc)
Male	3	3.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	1.3	nc	(nc-nc)	Male	2	4.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	15	13.4	111.8	(62.5-184.5)
Male	12	10.3	116.0	(59.9-202.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	7.6	79.3	(29.0-172.6)	Female	17	23.4	72.7	(42.3-116.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	8.3	96.6	(41.6-190.3)	Male	396	332.8	119.0	(107.6-131.3)
Female	2	3.4	nc	(nc-nc)	Female	363	355.1	102.2	(92.0-113.3)
<b><u>Lung and Bronchus</u></b>									
Male	45	51.7	87.1	(63.5-116.5)					
Female	58	58.6	98.9	(75.1-127.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dighton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	8.8	113.9	(54.5-209.4)	Male	7	5.5	128.1	(51.3-263.9)
Female	1	2.5	nc	(nc-nc)	Female	4	3.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	5	4.8	103.2	(33.2-240.7)
Female	19	28.2	67.3	(40.5-105.0)	Female	3	3.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.5	nc	(nc-nc)
Male	13	9.4	137.8	(73.3-235.7)	<b><u>Ovary</u></b>				
Female	5	7.5	66.7	(21.5-155.7)	Female	3	2.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	22	25.4	86.7	(54.3-131.2)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.1	nc	(nc-nc)
Male	3	4.6	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	5	2.3	220.7	(71.1-515.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.1	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	4	2.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	5.2	nc	(nc-nc)
Male	1	3.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	2.1	nc	(nc-nc)	Female	7	6.2	113.4	(45.4-233.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.0	nc	(nc-nc)	Male	102	109.6	93.1	(75.9-113.0)
Female	2	0.8	nc	(nc-nc)	Female	79	95.2	83.0	(65.7-103.5)
<b><u>Lung and Bronchus</u></b>									
Male	8	15.4	51.9	(22.4-102.3)					
Female	14	13.4	104.3	(57.0-175.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Douglas

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	7.7	90.3	(36.2-186.1)	Male	9	5.4	166.2	(75.8-315.5)
Female	5	2.0	248.5	(80.1-580.0)	Female	3	3.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.7	nc	(nc-nc)	Male	4	1.8	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	4	4.9	nc	(nc-nc)
Female	33	31.3	105.4	(72.6-148.1)	Female	1	3.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.2	nc	(nc-nc)	Male	5	4.3	116.3	(37.5-271.5)
<b><u>Colon / Rectum</u></b>					Female	1	1.5	nc	(nc-nc)
Male	6	9.0	66.8	(24.4-145.5)	<b><u>Ovary</u></b>				
Female	8	6.3	126.7	(54.6-249.7)	Female	2	2.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.2	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	2.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	24	27.4	87.4	(56.0-130.1)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.0	nc	(nc-nc)
Male	9	4.9	182.6	(83.3-346.7)	Female	0	0.8	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.2	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	5	2.4	208.5	(67.2-486.5)
<b><u>Leukemia</u></b>					Female	8	6.6	121.4	(52.3-239.2)
Male	1	3.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	1.9	nc	(nc-nc)	Female	9	7.1	126.4	(57.7-240.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.2	nc	(nc-nc)	Male	111	109.7	101.2	(83.2-121.8)
Female	0	0.8	nc	(nc-nc)	Female	105	95.0	110.6	(90.4-133.8)
<b><u>Lung and Bronchus</u></b>									
Male	14	14.4	96.9	(52.9-162.6)					
Female	14	11.7	119.3	(65.1-200.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dover

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	7.7	nc	(nc-nc)	Male	11	5.4	203.1	(101.3-363.5)
Female	0	2.0	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	7	4.9	144.0	(57.7-296.7)
Female	28	25.6	109.2	(72.5-157.8)	Female	3	3.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	2	4.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.3	nc	(nc-nc)
Male	7	9.0	78.0	(31.2-160.7)	<b><u>Ovary</u></b>				
Female	3	6.0	nc	(nc-nc)	Female	0	2.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	23	27.4	83.8	(53.1-125.8)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.0	nc	(nc-nc)
Male	4	4.9	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.2	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	5	2.4	208.5	(67.2-486.5)
<b><u>Leukemia</u></b>					Female	5	4.5	111.8	(36.0-261.0)
Male	1	3.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.6	nc	(nc-nc)	Female	3	5.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	3.2	nc	(nc-nc)	Male	91	109.7	82.9	(66.8-101.8)
Female	0	0.7	nc	(nc-nc)	Female	66	81.4	81.0	(62.7-103.1)
<b><u>Lung and Bronchus</u></b>									
Male	9	14.4	62.3	(28.4-118.3)					
Female	7	11.3	62.1	(24.9-127.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dracut

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	40	29.8	134.3	(95.9-182.8)	Male	13	19.9	65.4	(34.8-111.8)
Female	20	10.5	190.5	(116.3-294.2)	Female	15	15.7	95.8	(53.6-158.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	6.4	125.2	(53.9-246.8)	Male	7	6.3	111.0	(44.5-228.8)
Female	5	5.0	100.1	(32.3-233.7)	Female	3	4.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	14	17.7	79.2	(43.2-132.8)
Female	135	126.9	106.4	(89.2-125.9)	Female	14	15.2	91.9	(50.2-154.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	4.4	135.5	(49.5-295.0)	Male	10	15.6	64.2	(30.8-118.1)
<b><u>Colon / Rectum</u></b>					Female	10	6.5	154.1	(73.8-283.4)
Male	40	33.1	120.8	(86.3-164.4)	<b><u>Ovary</u></b>				
Female	44	30.9	142.2	(103.3-191.0)	Female	11	10.8	102.1	(50.9-182.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	13	8.1	159.6	(84.9-272.9)	Male	9	10.9	82.3	(37.5-156.2)
Female	5	2.1	239.3	(77.1-558.4)	Female	14	10.5	133.0	(72.6-223.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	2.5	nc	(nc-nc)	Male	96	103.1	93.1	(75.4-113.7)
Female	2	2.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	11	7.4	149.5	(74.5-267.6)
Male	21	18.0	116.5	(72.1-178.1)	Female	5	4.2	119.2	(38.4-278.2)
Female	14	9.9	141.3	(77.2-237.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	4.7	107.5	(34.6-250.9)
Male	8	4.8	167.7	(72.2-330.5)	<b><u>Thyroid</u></b>				
Female	1	1.4	nc	(nc-nc)	Male	5	8.4	59.8	(19.3-139.5)
<b><u>Leukemia</u></b>					Female	23	24.6	93.5	(59.2-140.3)
Male	18	12.7	142.0	(84.1-224.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	8.8	102.1	(46.6-193.9)	Female	21	28.4	73.9	(45.7-113.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	10	11.3	88.2	(42.2-162.2)	Male	441	407.9	108.1	(98.3-118.7)
Female	5	3.6	139.0	(44.8-324.5)	Female	480	415.0	115.7	(105.5-126.5)
<b><u>Lung and Bronchus</u></b>									
Male	64	54.8	116.7	(89.9-149.0)					
Female	73	56.8	128.6	(100.8-161.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dudley

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	11.1	99.3	(49.5-177.7)	Male	6	7.2	83.0	(30.3-180.8)
Female	4	3.1	nc	(nc-nc)	Female	5	5.0	100.3	(32.3-234.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.3	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	4	6.6	nc	(nc-nc)
Female	45	40.7	110.6	(80.7-148.0)	Female	5	4.7	106.3	(34.3-248.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.5	nc	(nc-nc)	Male	3	5.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	2.0	nc	(nc-nc)
Male	13	12.0	108.6	(57.8-185.8)	<b><u>Ovary</u></b>				
Female	11	9.5	115.6	(57.6-206.9)	Female	4	3.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.8	nc	(nc-nc)	Male	5	4.0	126.3	(40.7-294.7)
Female	3	0.6	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	34	33.0	102.9	(71.2-143.8)
Female	2	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	2.7	185.1	(59.6-431.9)
Male	11	6.2	177.3	(88.4-317.2)	Female	0	1.3	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.9	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	11	8.3	132.2	(65.9-236.6)
Male	10	4.7	212.9	(101.9-391.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	2.7	181.9	(58.6-424.4)	Female	17	9.0	188.6	(109.8-302.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	3.8	nc	(nc-nc)	Male	155	143.7	107.9	(91.6-126.3)
Female	1	1.1	nc	(nc-nc)	Female	167	130.5	128.0	(109.3-148.9)
<b><u>Lung and Bronchus</u></b>									
Male	25	19.7	126.7	(82.0-187.0)					
Female	24	17.0	141.2	(90.4-210.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dunstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	3.1	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	0.7	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	15	15.1	99.4	(55.6-164.0)	Female	2	1.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	0.8	nc	(nc-nc)
Male	4	3.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	3.5	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	0.9	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	10	11.9	84.0	(40.2-154.5)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.8	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	0.4	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	2.9	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.0	nc	(nc-nc)	Female	5	3.4	147.8	(47.6-345.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	41	45.1	90.9	(65.2-123.3)
Female	0	0.4	nc	(nc-nc)	Female	45	47.3	95.1	(69.4-127.3)
<b><u>Lung and Bronchus</u></b>									
Male	2	5.9	nc	(nc-nc)					
Female	9	6.0	151.3	(69.0-287.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Duxbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	26	18.6	140.0	(91.4-205.1)	Male	30	11.5	260.2	(175.5-371.5)
Female	2	6.3	nc	(nc-nc)	Female	13	8.6	151.6	(80.6-259.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	3.5	144.6	(46.6-337.5)	Male	9	3.9	233.8	(106.7-443.8)
Female	1	2.8	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	18	10.5	172.1	(101.9-272.0)
Female	86	72.7	118.3	(94.6-146.1)	Female	6	8.9	67.6	(24.7-147.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.2	nc	(nc-nc)	Male	5	8.8	56.7	(18.3-132.3)
<b><u>Colon / Rectum</u></b>					Female	4	3.8	nc	(nc-nc)
Male	10	20.0	49.9	(23.9-91.7)	<b><u>Ovary</u></b>				
Female	11	18.9	58.3	(29.1-104.4)	Female	8	6.2	129.7	(55.8-255.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	4.8	nc	(nc-nc)	Male	5	6.6	75.4	(24.3-176.1)
Female	1	1.2	nc	(nc-nc)	Female	7	6.5	107.8	(43.2-222.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	81	59.6	135.9	(107.9-168.9)
Female	0	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	4.5	nc	(nc-nc)
Male	15	10.4	144.9	(81.1-239.0)	Female	0	2.6	nc	(nc-nc)
Female	2	5.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.7	nc	(nc-nc)
Male	1	2.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	2	4.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	12.4	64.6	(27.8-127.3)
Male	7	7.4	94.3	(37.8-194.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	5.0	119.0	(43.5-259.1)	Female	9	16.1	55.9	(25.5-106.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	6.5	nc	(nc-nc)	Male	266	239.1	111.3	(98.3-125.5)
Female	0	2.1	nc	(nc-nc)	Female	212	238.6	88.9	(77.3-101.7)
<b><u>Lung and Bronchus</u></b>									
Male	26	32.9	78.9	(51.5-115.7)					
Female	21	33.0	63.7	(39.4-97.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# East Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	13.5	103.4	(56.5-173.5)	Male	12	9.0	132.6	(68.4-231.6)
Female	3	5.9	nc	(nc-nc)	Female	9	8.1	111.5	(50.9-211.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.8	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	10	8.1	123.2	(59.0-226.5)
Female	45	67.6	66.6	(48.6-89.1)	Female	11	8.3	132.7	(66.2-237.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.2	nc	(nc-nc)	Male	9	7.0	128.9	(58.8-244.6)
<b><u>Colon / Rectum</u></b>					Female	1	3.5	nc	(nc-nc)
Male	21	15.2	138.3	(85.6-211.4)	<b><u>Ovary</u></b>				
Female	10	17.0	58.8	(28.1-108.1)	Female	7	5.8	121.7	(48.8-250.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	3.6	137.3	(44.2-320.3)	Male	3	5.0	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	7	6.0	116.8	(46.8-240.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	50	45.1	110.8	(82.3-146.1)
Female	2	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	3.4	nc	(nc-nc)
Male	13	8.2	158.6	(84.3-271.2)	Female	2	2.3	nc	(nc-nc)
Female	5	5.3	93.8	(30.2-218.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.0	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	11	11.9	92.3	(46.0-165.1)
Male	3	5.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	4.7	nc	(nc-nc)	Female	11	15.3	71.8	(35.8-128.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	5.0	100.4	(32.4-234.4)	Male	198	183.4	108.0	(93.5-124.1)
Female	1	1.9	nc	(nc-nc)	Female	178	223.6	79.6	(68.4-92.2)
<b><u>Lung and Bronchus</u></b>									
Male	26	24.9	104.4	(68.2-153.0)					
Female	26	32.0	81.3	(53.1-119.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# East Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	2.9	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	5	10.6	47.2	(15.2-110.2)	Female	0	1.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.5	nc	(nc-nc)
Male	4	3.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	2.4	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	10	9.0	111.2	(53.2-204.5)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.7	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	2.0	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.7	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	34	36.2	94.0	(65.1-131.4)
Female	0	0.3	nc	(nc-nc)	Female	25	33.7	74.3	(48.0-109.6)
<b><u>Lung and Bronchus</u></b>									
Male	3	4.9	nc	(nc-nc)					
Female	6	4.6	131.5	(48.0-286.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# East Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	16	20.8	77.0	(44.0-125.0)	Male	18	12.6	143.3	(84.9-226.5)
Female	5	8.4	59.5	(19.2-138.9)	Female	9	10.2	88.5	(40.4-168.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.6	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
Female	3	3.2	nc	(nc-nc)	Female	4	3.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	10	11.3	88.2	(42.2-162.2)
Female	83	81.7	101.6	(80.9-125.9)	Female	7	11.2	62.5	(25.0-128.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.5	nc	(nc-nc)	Male	8	9.1	87.6	(37.7-172.6)
<b><u>Colon / Rectum</u></b>					Female	3	4.6	nc	(nc-nc)
Male	24	21.8	110.0	(70.4-163.6)	<b><u>Ovary</u></b>				
Female	32	24.3	131.5	(89.9-185.6)	Female	14	7.2	194.6	(106.3-326.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	5.2	nc	(nc-nc)	Male	6	7.2	83.0	(30.3-180.6)
Female	1	1.6	nc	(nc-nc)	Female	10	8.6	116.2	(55.6-213.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	51	61.6	82.8	(61.7-108.9)
Female	0	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	4.9	122.6	(44.8-266.9)
Male	15	10.8	139.1	(77.8-229.4)	Female	6	3.4	178.9	(65.3-389.5)
Female	5	6.7	74.5	(24.0-173.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.0	nc	(nc-nc)
Male	2	3.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	3	4.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	12	13.3	90.6	(46.7-158.2)
Male	5	8.0	62.4	(20.1-145.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	6.5	nc	(nc-nc)	Female	17	18.1	94.1	(54.8-150.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	6.7	nc	(nc-nc)	Male	234	256.5	91.2	(79.9-103.7)
Female	1	2.6	nc	(nc-nc)	Female	290	287.1	101.0	(89.7-113.3)
<b><u>Lung and Bronchus</u></b>									
Male	37	36.1	102.5	(72.2-141.3)					
Female	52	42.3	123.0	(91.9-161.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Eastham

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	11.2	98.0	(48.9-175.4)	Male	7	6.3	111.9	(44.8-230.5)
Female	2	3.5	nc	(nc-nc)	Female	12	4.0	300.8	(155.2-525.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.6	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	5	5.5	90.3	(29.1-210.6)
Female	52	34.2	152.2	(113.6-199.6)	Female	4	4.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	6	4.4	135.5	(49.5-294.8)
<b><u>Colon / Rectum</u></b>					Female	2	1.9	nc	(nc-nc)
Male	10	10.8	92.8	(44.4-170.7)	<b><u>Ovary</u></b>				
Female	11	9.4	117.1	(58.4-209.6)	Female	3	3.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.7	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	5	3.5	142.3	(45.8-332.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	40	33.1	120.8	(86.3-164.5)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.5	nc	(nc-nc)
Male	6	5.3	114.2	(41.7-248.7)	Female	2	1.3	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.5	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	4.7	nc	(nc-nc)
Male	8	4.0	201.3	(86.7-396.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.5	nc	(nc-nc)	Female	4	8.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	3.4	nc	(nc-nc)	Male	149	131.6	113.3	(95.8-133.0)
Female	1	1.1	nc	(nc-nc)	Female	133	118.3	112.4	(94.1-133.2)
<b><u>Lung and Bronchus</u></b>									
Male	23	19.6	117.1	(74.2-175.7)					
Female	12	18.8	63.8	(32.9-111.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Easthampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	17.9	72.7	(38.7-124.3)	Male	8	11.9	67.4	(29.0-132.7)
Female	3	7.2	nc	(nc-nc)	Female	7	9.8	71.6	(28.7-147.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	3.6	140.4	(45.2-327.6)	Male	3	3.8	nc	(nc-nc)
Female	1	3.0	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	13	10.5	123.2	(65.6-210.8)
Female	76	77.8	97.7	(77.0-122.3)	Female	9	10.0	90.1	(41.1-171.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.6	nc	(nc-nc)	Male	11	9.2	119.5	(59.6-213.9)
<b><u>Colon / Rectum</u></b>					Female	5	4.2	119.4	(38.5-278.7)
Male	29	19.9	145.4	(97.4-208.8)	<b><u>Ovary</u></b>				
Female	22	21.1	104.4	(65.4-158.1)	Female	1	6.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	4.8	nc	(nc-nc)	Male	4	6.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	11	7.2	151.9	(75.7-271.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	49	60.2	81.4	(60.2-107.7)
Female	0	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	4.4	112.6	(36.3-262.8)
Male	10	10.6	94.4	(45.2-173.6)	Female	2	2.8	nc	(nc-nc)
Female	8	6.2	128.7	(55.4-253.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.5	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	0	4.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	14.3	48.9	(19.6-100.9)
Male	4	7.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	5.6	nc	(nc-nc)	Female	19	17.4	109.2	(65.7-170.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	6.7	nc	(nc-nc)	Male	203	241.0	84.2	(73.0-96.6)
Female	4	2.4	nc	(nc-nc)	Female	238	263.9	90.2	(79.1-102.4)
<b><u>Lung and Bronchus</u></b>									
Male	29	32.6	89.1	(59.6-127.9)					
Female	35	37.4	93.6	(65.2-130.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Easton

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	27	21.0	128.3	(84.5-186.7)	Male	20	14.3	140.0	(85.5-216.3)
Female	11	7.0	156.8	(78.2-280.6)	Female	14	10.9	128.3	(70.1-215.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	4.7	128.3	(46.9-279.3)	Male	4	4.6	nc	(nc-nc)
Female	4	3.6	nc	(nc-nc)	Female	5	3.3	150.8	(48.6-351.9)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	12	12.9	93.2	(48.1-162.8)
Female	110	88.9	123.8	(101.7-149.2)	Female	9	10.5	85.9	(39.2-163.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.1	nc	(nc-nc)	Male	9	11.4	79.0	(36.0-150.0)
<b><u>Colon / Rectum</u></b>					Female	4	4.5	nc	(nc-nc)
Male	12	23.9	50.1	(25.9-87.6)	<b><u>Ovary</u></b>				
Female	30	20.9	143.6	(96.9-205.1)	Female	9	7.5	119.8	(54.7-227.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	5.9	nc	(nc-nc)	Male	12	7.8	153.4	(79.2-267.9)
Female	3	1.4	nc	(nc-nc)	Female	8	7.1	113.5	(48.9-223.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	87	74.9	116.1	(93.0-143.3)
Female	0	1.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	5.3	nc	(nc-nc)
Male	13	13.2	98.4	(52.4-168.4)	Female	3	2.9	nc	(nc-nc)
Female	4	6.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	3.5	nc	(nc-nc)
Male	2	3.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	10	6.2	160.7	(76.9-295.5)
<b><u>Leukemia</u></b>					Female	19	17.8	107.0	(64.4-167.1)
Male	15	9.1	164.2	(91.9-270.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	6.1	nc	(nc-nc)	Female	17	19.9	85.4	(49.7-136.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	13	8.2	158.6	(84.3-271.2)	Male	317	294.6	107.6	(96.1-120.1)
Female	4	2.5	nc	(nc-nc)	Female	339	287.0	118.1	(105.9-131.4)
<b><u>Lung and Bronchus</u></b>									
Male	40	39.1	102.4	(73.1-139.4)					
Female	49	38.1	128.7	(95.2-170.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Edgartown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	7.0	100.6	(40.3-207.4)	Male	17	4.5	378.0	(220.1-605.3)
Female	1	1.6	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
Female	24	17.7	135.9	(87.0-202.2)	Female	3	2.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.6	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	0.9	nc	(nc-nc)
Male	10	7.6	132.2	(63.3-243.1)	<b><u>Ovary</u></b>				
Female	4	4.6	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	0	2.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	24	25.5	94.1	(60.3-140.1)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.7	nc	(nc-nc)
Male	0	4.2	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.8	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	3.0	197.8	(72.2-430.5)
Male	2	2.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.2	nc	(nc-nc)	Female	0	4.0	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.7	nc	(nc-nc)	Male	91	95.0	95.8	(77.1-117.6)
Female	0	0.5	nc	(nc-nc)	Female	64	58.6	109.1	(84.0-139.4)
<b><u>Lung and Bronchus</u></b>									
Male	10	12.6	79.5	(38.0-146.2)					
Female	10	8.2	121.2	(58.0-222.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Egremont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	2.5	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	6	7.2	83.4	(30.5-181.6)	Female	1	1.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	5	2.5	202.0	(65.1-471.4)	<b><u>Ovary</u></b>				
Female	0	2.1	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	6	7.8	77.0	(28.1-167.6)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.6	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.0	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.6	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	23	30.4	75.7	(48.0-113.6)
Female	0	0.2	nc	(nc-nc)	Female	22	25.3	86.9	(54.4-131.5)
<b><u>Lung and Bronchus</u></b>									
Male	0	4.4	nc	(nc-nc)					
Female	3	3.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Erving

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	6	7.7	77.6	(28.4-169.0)	Female	2	0.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	3	2.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	2.0	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	6.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.5	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.5	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.6	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	15	24.7	60.8	(34.0-100.3)
Female	0	0.2	nc	(nc-nc)	Female	21	25.6	81.9	(50.7-125.3)
<b><u>Lung and Bronchus</u></b>									
Male	4	3.3	nc	(nc-nc)					
Female	3	3.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Essex

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	4.5	155.3	(62.2-320.0)	Male	8	2.9	276.8	(119.2-545.4)
Female	1	1.3	nc	(nc-nc)	Female	0	2.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	3	0.6	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	13	16.5	78.7	(41.8-134.5)	Female	2	1.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	5	2.2	222.3	(71.6-518.8)
<b><u>Colon / Rectum</u></b>					Female	0	0.8	nc	(nc-nc)
Male	1	4.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	3	3.8	nc	(nc-nc)	Female	4	1.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	8	15.3	52.4	(22.5-103.2)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.1	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.5	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	3.1	nc	(nc-nc)
Male	3	1.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.0	nc	(nc-nc)	Female	1	3.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.6	nc	(nc-nc)	Male	62	59.9	103.6	(79.4-132.8)
Female	0	0.5	nc	(nc-nc)	Female	49	52.6	93.2	(69.0-123.3)
<b><u>Lung and Bronchus</u></b>									
Male	11	8.2	134.8	(67.2-241.2)					
Female	8	7.1	112.7	(48.5-222.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Everett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	33	36.5	90.3	(62.2-126.8)	Male	18	24.4	73.6	(43.6-116.4)
Female	12	13.2	90.8	(46.9-158.6)	Female	7	20.5	34.1	(13.7-70.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	8.1	nc	(nc-nc)	Male	9	7.6	118.3	(54.0-224.6)
Female	2	6.5	nc	(nc-nc)	Female	2	6.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	17	21.9	77.8	(45.3-124.5)
Female	139	157.3	88.4	(74.3-104.3)	Female	19	19.3	98.2	(59.1-153.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	16	6.1	264.3	(151.0-429.3)	Male	20	17.9	111.4	(68.0-172.1)
<b><u>Colon / Rectum</u></b>					Female	10	8.1	123.4	(59.1-226.9)
Male	39	40.6	96.0	(68.2-131.2)	<b><u>Ovary</u></b>				
Female	30	40.9	73.3	(49.4-104.6)	Female	11	13.4	82.1	(40.9-147.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	14	9.4	148.6	(81.1-249.3)	Male	9	13.0	69.0	(31.5-131.1)
Female	1	2.5	nc	(nc-nc)	Female	15	13.5	110.9	(62.0-182.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	3.7	nc	(nc-nc)	Male	97	110.9	87.4	(70.9-106.7)
Female	3	2.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	17	9.0	189.6	(110.4-303.5)
Male	28	21.3	131.4	(87.3-189.9)	Female	6	5.6	108.1	(39.5-235.3)
Female	17	12.2	139.6	(81.3-223.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	7.3	68.9	(22.2-160.7)
Male	6	5.5	109.0	(39.8-237.3)	<b><u>Thyroid</u></b>				
Female	2	1.6	nc	(nc-nc)	Male	12	10.7	112.5	(58.1-196.6)
<b><u>Leukemia</u></b>					Female	27	33.8	79.8	(52.6-116.1)
Male	15	15.9	94.5	(52.8-155.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	11	11.6	94.9	(47.3-169.8)	Female	27	33.2	81.4	(53.7-118.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	20	12.9	155.0	(94.6-239.4)	Male	467	483.4	96.6	(88.0-105.8)
Female	6	4.4	137.9	(50.4-300.2)	Female	485	523.1	92.7	(84.6-101.3)
<b><u>Lung and Bronchus</u></b>									
Male	71	65.8	107.8	(84.2-136.0)					
Female	84	68.4	122.8	(98.0-152.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Fairhaven

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	23	21.1	108.9	(69.0-163.4)	Male	5	13.0	38.5	(12.4-89.9)
Female	18	8.6	209.4	(124.1-331.0)	Female	7	10.6	65.9	(26.4-135.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.7	nc	(nc-nc)	Male	5	4.2	118.3	(38.1-276.2)
Female	4	3.3	nc	(nc-nc)	Female	2	3.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	9	11.6	77.3	(35.3-146.7)
Female	79	84.6	93.4	(73.9-116.4)	Female	15	11.5	131.0	(73.2-216.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.6	nc	(nc-nc)	Male	7	9.7	72.4	(29.0-149.1)
<b><u>Colon / Rectum</u></b>					Female	2	4.8	nc	(nc-nc)
Male	10	22.3	44.9	(21.5-82.5)	<b><u>Ovary</u></b>				
Female	19	24.9	76.4	(46.0-119.4)	Female	14	7.5	187.3	(102.3-314.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	5.4	nc	(nc-nc)	Male	6	7.5	80.4	(29.3-174.9)
Female	2	1.6	nc	(nc-nc)	Female	9	8.9	101.5	(46.3-192.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	60	66.7	90.0	(68.6-115.8)
Female	0	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	5.0	99.9	(32.2-233.1)
Male	17	11.3	149.9	(87.3-240.1)	Female	3	3.4	nc	(nc-nc)
Female	8	7.0	115.0	(49.5-226.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	2.1	nc	(nc-nc)
Male	4	3.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	2	4.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	12	14.0	85.6	(44.2-149.5)
Male	7	8.1	85.9	(34.4-177.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	11	6.6	165.7	(82.6-296.5)	Female	19	19.0	99.8	(60.0-155.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	7.1	nc	(nc-nc)	Male	236	267.2	88.3	(77.4-100.3)
Female	1	2.7	nc	(nc-nc)	Female	289	296.5	97.5	(86.6-109.4)
<b><u>Lung and Bronchus</u></b>									
Male	42	37.1	113.1	(81.5-152.9)					
Female	39	43.3	90.0	(64.0-123.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Fall River

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	101	85.8	117.7	(95.9-143.0)	Male	31	55.2	56.2	(38.2-79.8)
Female	39	37.8	103.2	(73.4-141.0)	Female	25	50.3	49.7	(32.1-73.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	18	17.3	103.8	(61.5-164.1)	Male	12	17.5	68.5	(35.3-119.6)
Female	10	16.1	62.2	(29.8-114.4)	Female	16	16.9	94.4	(53.9-153.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	3.0	nc	(nc-nc)	Male	42	49.7	84.5	(60.9-114.2)
Female	328	395.2	83.0	(74.3-92.5)	Female	49	52.0	94.2	(69.7-124.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	17	13.2	128.4	(74.7-205.5)	Male	41	40.9	100.3	(71.9-136.0)
<b><u>Colon / Rectum</u></b>					Female	18	21.6	83.5	(49.4-131.9)
Male	109	93.2	117.0	(96.0-141.1)	<b><u>Ovary</u></b>				
Female	112	110.6	101.3	(83.4-121.9)	Female	16	34.5	46.4	(26.5-75.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	21	22.1	95.2	(58.9-145.5)	Male	30	30.7	97.8	(66.0-139.7)
Female	4	7.3	nc	(nc-nc)	Female	49	38.7	126.7	(93.7-167.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	10	7.3	137.0	(65.6-252.0)	Male	291	269.6	107.9	(95.9-121.1)
Female	7	6.4	108.9	(43.6-224.3)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	30	20.7	144.6	(97.5-206.5)
Male	50	48.3	103.5	(76.8-136.4)	Female	26	15.1	172.4	(112.6-252.7)
Female	32	31.9	100.2	(68.5-141.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	10	13.6	73.4	(35.1-134.9)
Male	20	12.8	156.3	(95.4-241.4)	<b><u>Thyroid</u></b>				
Female	8	4.5	176.8	(76.1-348.4)	Male	15	22.6	66.5	(37.2-109.7)
<b><u>Leukemia</u></b>					Female	81	73.2	110.7	(87.9-137.6)
Male	40	35.6	112.4	(80.3-153.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	35	30.5	114.8	(79.9-159.6)	Female	95	86.8	109.4	(88.5-133.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	31	29.6	104.7	(71.1-148.6)	Male	1233	1117.9	110.3	(104.2-116.6)
Female	14	12.0	116.8	(63.8-195.9)	Female	1313	1363.3	96.3	(91.2-101.7)
<b><u>Lung and Bronchus</u></b>									
Male	236	152.5	154.8	(135.7-175.9)					
Female	211	194.5	108.5	(94.3-124.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Falmouth

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	53	56.6	93.7	(70.2-122.5)	Male	33	32.2	102.5	(70.5-143.9)
Female	13	20.5	63.4	(33.7-108.4)	Female	36	23.4	154.0	(107.9-213.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	14	8.6	163.0	(89.0-273.5)	Male	6	10.7	56.2	(20.5-122.4)
Female	9	7.4	122.3	(55.8-232.2)	Female	8	9.0	88.9	(38.3-175.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	35	28.8	121.6	(84.7-169.1)
Female	208	196.3	106.0	(92.0-121.4)	Female	18	26.7	67.5	(40.0-106.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	5.4	nc	(nc-nc)	Male	29	22.1	131.3	(87.9-188.6)
<b><u>Colon / Rectum</u></b>					Female	9	11.0	82.0	(37.4-155.6)
Male	43	55.2	77.9	(56.4-105.0)	<b><u>Ovary</u></b>				
Female	53	56.2	94.3	(70.6-123.4)	Female	20	17.2	116.4	(71.1-179.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	12	13.4	89.3	(46.1-156.0)	Male	12	19.1	62.9	(32.5-109.8)
Female	6	4.0	150.0	(54.8-326.4)	Female	13	20.8	62.6	(33.3-107.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	2.7	nc	(nc-nc)	Male	169	159.0	106.3	(90.9-123.6)
Female	1	2.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	12	12.9	93.2	(48.1-162.9)
Male	32	26.6	120.1	(82.1-169.6)	Female	5	7.6	65.6	(21.2-153.2)
Female	16	16.4	97.4	(55.6-158.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	3.7	nc	(nc-nc)
Male	12	7.7	155.7	(80.3-272.0)	<b><u>Thyroid</u></b>				
Female	2	2.4	nc	(nc-nc)	Male	7	9.9	70.5	(28.3-145.3)
<b><u>Leukemia</u></b>					Female	14	28.3	49.5	(27.0-83.0)
Male	22	20.5	107.2	(67.2-162.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	14.8	54.0	(23.2-106.3)	Female	33	45.1	73.1	(50.3-102.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	16	17.0	94.4	(53.9-153.2)	Male	648	662.8	97.8	(90.4-105.6)
Female	4	6.4	nc	(nc-nc)	Female	643	686.9	93.6	(86.5-101.1)
<b><u>Lung and Bronchus</u></b>									
Male	76	99.7	76.2	(60.0-95.4)					
Female	113	107.9	104.7	(86.3-125.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Fitchburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	56	36.6	152.9	(115.5-198.6)	Male	13	24.2	53.8	(28.6-92.0)
Female	16	13.8	115.8	(66.1-188.1)	Female	10	19.1	52.4	(25.1-96.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	8.0	nc	(nc-nc)	Male	6	7.6	78.6	(28.7-171.1)
Female	12	6.3	191.0	(98.6-333.7)	Female	7	6.2	112.7	(45.2-232.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	13	21.8	59.7	(31.8-102.1)
Female	143	149.0	96.0	(80.9-113.1)	Female	19	19.2	98.9	(59.5-154.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	11	5.1	216.0	(107.7-386.5)	Male	23	18.2	126.6	(80.3-190.0)
<b><u>Colon / Rectum</u></b>					Female	9	8.0	112.3	(51.3-213.2)
Male	37	40.3	91.7	(64.6-126.4)	<b><u>Ovary</u></b>				
Female	43	40.1	107.1	(77.5-144.3)	Female	13	13.0	99.9	(53.2-170.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	9.6	72.7	(29.1-149.8)	Male	13	13.2	98.5	(52.4-168.5)
Female	1	2.7	nc	(nc-nc)	Female	6	14.0	43.0	(15.7-93.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	3.6	nc	(nc-nc)	Male	99	118.1	83.8	(68.1-102.0)
Female	0	2.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	15	8.9	167.6	(93.7-276.5)
Male	24	21.3	112.7	(72.2-167.7)	Female	7	5.5	128.4	(51.4-264.5)
Female	12	12.1	99.5	(51.3-173.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	6.7	88.9	(32.5-193.6)
Male	2	5.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	1.7	nc	(nc-nc)	Male	6	10.3	58.3	(21.3-127.0)
<b><u>Leukemia</u></b>					Female	27	28.9	93.4	(61.5-135.9)
Male	14	15.8	88.7	(48.5-148.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	13	11.4	113.7	(60.5-194.5)	Female	26	32.8	79.4	(51.8-116.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	18	13.2	136.2	(80.7-215.3)	Male	486	489.4	99.3	(90.7-108.5)
Female	6	4.5	134.7	(49.2-293.2)	Female	519	510.6	101.7	(93.1-110.8)
<b><u>Lung and Bronchus</u></b>									
Male	86	65.8	130.7	(104.5-161.4)					
Female	85	72.7	116.9	(93.4-144.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Florida

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	3	4.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	1.0	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	3.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	1	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	0.7	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.3	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	8	12.1	66.2	(28.5-130.5)
Female	0	0.1	nc	(nc-nc)	Female	8	13.5	59.4	(25.6-117.0)
<b><u>Lung and Bronchus</u></b>									
Male	0	1.6	nc	(nc-nc)					
Female	1	1.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Foxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	17.5	68.7	(35.4-120.0)	Male	21	11.3	185.0	(114.5-282.9)
Female	3	6.3	nc	(nc-nc)	Female	10	9.2	108.7	(52.0-199.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	3.5	201.2	(80.6-414.7)	Male	2	3.7	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	2	2.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	12	10.2	117.6	(60.7-205.4)
Female	87	76.5	113.7	(91.1-140.2)	Female	7	9.1	76.6	(30.7-157.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.6	nc	(nc-nc)	Male	7	8.6	81.1	(32.5-167.2)
<b><u>Colon / Rectum</u></b>					Female	0	3.9	nc	(nc-nc)
Male	21	19.5	107.5	(66.5-164.3)	<b><u>Ovary</u></b>				
Female	19	18.3	104.1	(62.6-162.6)	Female	8	6.5	123.8	(53.3-243.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	4.6	131.6	(48.1-286.5)	Male	3	6.3	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	5	6.2	80.4	(25.9-187.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	5	1.4	366.9	(118.2-856.2)	Male	66	54.2	121.7	(94.1-154.9)
Female	0	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	8	4.3	187.2	(80.6-368.8)
Male	12	10.0	119.7	(61.8-209.1)	Female	2	2.5	nc	(nc-nc)
Female	8	6.0	134.3	(57.8-264.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.4	nc	(nc-nc)
Male	0	2.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	8	4.7	170.4	(73.3-335.7)
<b><u>Leukemia</u></b>					Female	17	14.3	119.1	(69.3-190.6)
Male	10	7.2	139.1	(66.6-255.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	5.2	115.5	(42.2-251.3)	Female	20	17.3	115.7	(70.7-178.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	6.2	nc	(nc-nc)	Male	252	228.2	110.4	(97.2-124.9)
Female	1	2.2	nc	(nc-nc)	Female	267	248.4	107.5	(95.0-121.2)
<b><u>Lung and Bronchus</u></b>									
Male	30	30.7	97.6	(65.8-139.3)					
Female	43	34.6	124.4	(90.0-167.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Framingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	59	66.6	88.5	(67.4-114.2)	Male	42	43.1	97.4	(70.2-131.6)
Female	21	25.8	81.4	(50.4-124.5)	Female	27	37.0	73.1	(48.1-106.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	13.5	66.5	(30.4-126.3)	Male	14	13.6	102.6	(56.1-172.2)
Female	5	11.9	41.9	(13.5-97.7)	Female	11	11.7	93.7	(46.7-167.7)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	2.3	nc	(nc-nc)	Male	41	38.7	105.9	(76.0-143.6)
Female	288	287.3	100.3	(89.0-112.5)	Female	27	36.4	74.2	(48.9-107.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	18	10.3	175.6	(104.0-277.5)	Male	28	31.5	88.8	(59.0-128.4)
<b><u>Colon / Rectum</u></b>					Female	10	15.3	65.2	(31.2-120.0)
Male	64	72.2	88.7	(68.3-113.2)	<b><u>Ovary</u></b>				
Female	77	77.0	99.9	(78.9-124.9)	Female	27	24.8	108.7	(71.6-158.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	10	17.0	58.8	(28.1-108.1)	Male	34	23.8	142.7	(98.8-199.4)
Female	5	5.0	100.2	(32.3-233.9)	Female	29	26.5	109.4	(73.2-157.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	5.6	nc	(nc-nc)	Male	201	204.1	98.5	(85.3-113.1)
Female	9	5.0	179.4	(81.9-340.6)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	22	16.2	136.0	(85.2-205.9)
Male	50	37.3	133.9	(99.4-176.5)	Female	8	10.5	76.3	(32.8-150.3)
Female	22	22.8	96.6	(60.5-146.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	9	10.8	83.4	(38.1-158.3)
Male	6	9.9	60.5	(22.1-131.8)	<b><u>Thyroid</u></b>				
Female	3	3.1	nc	(nc-nc)	Male	24	17.8	135.2	(86.6-201.1)
<b><u>Leukemia</u></b>					Female	62	57.1	108.5	(83.2-139.2)
Male	24	27.8	86.3	(55.3-128.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	21	21.9	96.1	(59.4-146.8)	Female	55	62.8	87.6	(66.0-114.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	27	23.1	117.0	(77.1-170.3)	Male	831	863.9	96.2	(89.8-103.0)
Female	7	8.4	83.2	(33.3-171.4)	Female	949	973.5	97.5	(91.4-103.9)
<b><u>Lung and Bronchus</u></b>									
Male	113	117.9	95.9	(79.0-115.2)					
Female	128	132.6	96.5	(80.5-114.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Franklin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	27	27.8	97.2	(64.0-141.4)	Male	21	18.7	112.1	(69.4-171.4)
Female	10	10.0	99.8	(47.8-183.6)	Female	17	15.3	111.0	(64.7-177.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	6.2	80.9	(26.1-188.8)	Male	11	5.9	185.8	(92.6-332.5)
Female	6	5.1	118.0	(43.1-256.8)	Female	5	4.7	107.4	(34.6-250.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	15	16.9	88.9	(49.7-146.6)
Female	136	124.1	109.6	(91.9-129.6)	Female	13	14.7	88.5	(47.1-151.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	7	4.5	156.8	(62.8-323.1)	Male	17	14.5	117.0	(68.1-187.3)
<b><u>Colon / Rectum</u></b>					Female	2	6.3	nc	(nc-nc)
Male	29	31.6	91.8	(61.5-131.9)	<b><u>Ovary</u></b>				
Female	27	30.6	88.2	(58.1-128.3)	Female	12	10.4	115.0	(59.3-200.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	10	7.5	134.2	(64.2-246.8)	Male	14	10.2	136.8	(74.7-229.5)
Female	1	2.0	nc	(nc-nc)	Female	7	10.2	68.9	(27.6-142.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	2.5	nc	(nc-nc)	Male	96	91.0	105.5	(85.5-128.8)
Female	5	2.1	242.5	(78.2-566.0)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	12	6.9	173.7	(89.7-303.5)
Male	14	16.9	82.8	(45.2-139.0)	Female	5	4.2	119.9	(38.6-279.7)
Female	17	9.5	178.5	(103.9-285.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	8	4.5	177.7	(76.5-350.2)
Male	9	4.3	207.0	(94.5-393.0)	<b><u>Thyroid</u></b>				
Female	0	1.3	nc	(nc-nc)	Male	16	8.2	195.3	(111.6-317.2)
<b><u>Leukemia</u></b>					Female	33	25.0	132.1	(90.9-185.5)
Male	12	12.2	98.4	(50.8-171.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	8.8	68.5	(25.0-149.2)	Female	38	26.7	142.4	(100.8-195.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	10.3	77.7	(33.5-153.1)	Male	398	377.5	105.4	(95.3-116.3)
Female	0	3.4	nc	(nc-nc)	Female	414	403.5	102.6	(93.0-113.0)
<b><u>Lung and Bronchus</u></b>									
Male	43	50.2	85.7	(62.0-115.4)					
Female	42	53.2	79.0	(56.9-106.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;